Business Context and Reporting Period
Company: BioXcel Therapeutics, Inc. (BTAI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 1, 2025
Event: Item 8.01 Other Events – Announcement of clinical trial milestone.
Key Financial Metrics
This filing is a current report regarding a clinical trial milestone and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Milestone
The Company announced the "last patient last visit" in the SERENITY At-Home Pivotal Phase 3 Safety Trial. Key details include:
- Indication: Acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting.
- Drug Candidate: BXCL501 (120 mcg dose).
- Study Design: Double-blind, placebo-controlled.
- Enrollment: More than 200 patients across 22 sites nationwide.
- Data Points: Over 2,200 agitation episodes collected.
- Completion: The vast majority of dosed patients completed the full 12-week study.
Guidance, Outlook, and Risks
Outlook: Topline results from the SERENITY At-Home trial are expected to be announced in August 2025. The Company anticipates an upcoming data release and a subsequent submission of a supplemental New Drug Application (sNDA).
Risks and Forward-Looking Statements: The filing contains extensive forward-looking statements regarding the data release and sNDA submission. Management notes that actual results could differ materially due to factors discussed in the "Risk Factors" section of the most recent Form 10-Q. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the release date and specific topline results of the SERENITY At-Home Phase 3 trial expected in August 2025.
- Confirm the timeline for the submission of the supplemental New Drug Application (sNDA) following the data release.
- Review the most recent Form 10-Q for updated risk factors affecting the commercialization of BXCL501.
- Monitor for any updates on the Company's cash position and burn rate, as this filing does not provide current liquidity data.